are live microorganisms, in most cases, bacteria, that are similar to or derived from beneficial microorganisms that are found in the human gut (e.g. for more information see Introduction to Probiotics
). They are also called "friendly bacteria" or "good bacteria." Enterologics intends to identify, in-license and develop unique probiotic strains for specific medical conditions, obtain regulatory approval and market these probiotics products as FDA-approved prescription drugs for specific label indications. The first probiotic product in its portfolio is E. coli M17, which is being developed for specific gastrointestinal indications.
For further information, contact firstname.lastname@example.org or visit www.enterologics.com.
Matters discussed in this release may constitute forward-looking statements. The U.S. Private Securities Litigation Reform Act of 1995 provides safe harbor protections for forward-looking statements in order to encourage companies to provide prospective information about their business. The Company desires to take advantage of the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and is including this cautionary statement in connection with this safe harbor legislation.
Forward-looking statements reflect our current views with respect to future events and financial performance and may include statements concerning plans, objectives, goals, strategies, future events or performance, and underlying assumptions and other statements, which are other than statements of historical facts. The words "believe," "intend," "anticipate," "estimate," "project," "forecast," "plan," "potential," "mayPage: 1 2 3 4 Related biology technology :1
. Oncolytics Biotech Inc. Completes Dose Escalation in Combination REOLYSIN(R)/Docetaxel Trial2
. Anthera Pharmaceuticals Completes $19 Million Financing; Appoints Christopher S. Henney as Chairman3
. Osprey Pharmaceuticals U.S.A., Inc. Completes $11 Million Initial Private Financing4
. Genesis Pharmaceuticals Completes Reverse Stock Split and Will Trade Under a New Symbol5
. Neptune Technologies successfully completes up to $8.5 million debt financing with Desjardins Group6
. Jennerex Completes $8.3 Million Series B Financing and Appoints Dr. Cal Stiller as Director7
. China Sky One Medical, Inc. Completes Acquisition of Peng Lai Jin Chuang Company8
. Novavax Completes Enrollment of Its Seasonal Influenza VLP Vaccine Phase IIa Clinical Trial9
. Roche completes acquisition of ARIUS10
. Water Street Health Care Partners Completes Agreement With Gentiva Health Services to Acquire Majority Ownership of CareCentrix11
. Memory Pharmaceuticals Completes Phase 1 Multiple Ascending Dose Study of R4996/MEM 63908